Counsel Patients on Nemolizumab for Eczema
July 2026
Nemolizumab (Nemluvio) will be a new biologic injection for moderate to severe eczema in patients 12 years and up.
It works by blocking interleukin-31...directly targeting pathways driving severe itching and inflammation...to help heal the skin.
About 1 in 7 patients on nemolizumab for 16 weeks achieve at least 75% improvement in eczema severity vs placebo...when combined with a topical corticosteroid and/or topical calcineurin inhibitor.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive